The author described retatrutide as a breakthrough in obesity treatment, saying that after 80 weeks, participants had lost an average of 25% of their weight, with less knee pain and fewer sleep apnea episodes. At a dose of 12 mg per week, weight loss was 28.3%, and 45.3% of participants lost at least 30% of their weight, the author wrote.
The author called for greater focus on younger people, citing rising obesity, nicotine use and other risk factors as serious concerns. They said prevention should begin early through increased awareness, healthier choices and tools to protect future health.
@Europarl_EN has also called for a science-based EU approach to #ultraprocessedfoods. Under the #SafeHeartsPlan, @EU_Commission is already taking this forward: our study will focus on what matters for public health: which ingredients&enzymes are linked to obesity&type 2 diabetes. #EU #PublicHealth #UltraProcessedFoods #EU #EU
Obesity, diabetes & cardiovascular diseases are closely linked & Europe must act earlier, prevent more & detect sooner. The #SafeHeartsPlan will support Member States and help improve cardiometabolic health. Thank you to #COTA Alliance for advancing this important discussion ⬇️ https://t.co/hIQ8c03hKX #Obesity #CardiometabolicHealth #PublicHealth #EU
Članek opozarja, da pomanjkanje spanca lahko vodi do povečanja telesne teže, kar je še posebej zaskrbljujoče, saj rak povezanim s težo postaja vse bolj smrtonosen. #deb obesity #rak #zdravje
Take care of acute and ongoing medical issues like obesity through any means necessary, but don't neglect the value of self-discovery even if the peptides work "well enough." Start personal growth with the body or start with the mind. But make sure to start. #SelfDiscovery #PersonalGrowth #HealthJourney #Thetweetdoesnotmentionanyspecificcountries.Therefore #therearenocountrycodestoreturn.
Cardiovascular disease, diabetes& obesity are closely linked & shouldn’t be addressed in isolation. That’s the philosophy behind #SafeHeartsPlan. We aim to reduce premature cardiovascular deaths by 25% by 2035 with prevention, earlier detection, screening & personalised care. #CardiovascularHealth #DiabetesCare #ObesityPrevention #Nospecificcountrycodescanbeidentifiedinthegiventweet.
Obesity in the EU: A Continent Divided by Progress and Persistence - trend report from Europeantrends.net For decades, obesity has been framed as a global tide, rising inexorably across nations and continents. Yet within the European Union, the reality is far more intricate, a patchwork of progress and stagnation, of early victories and lingering crises. While some member states have managed to halt, or even reverse, the growth of obesity among their populations, others continue to see rates climb, revealing deep fractures in public health, economic development, and cultural habits. https://europeantrends.net/2026/05/27/obesity-in-the-eu-continent-divided/ #health #obesity #wellbeing #EU
Vivek H. Murthy: Loneliness is not just a temporary state; it has real effects on health and on how society functions. Its impact on mortality is comparable to that of smoking up to 15 cigarettes a day — and even greater than that of obesity or lack of exercise.
GLP-1 weight loss injections, which have revolutionized obesity treatment with around 100 million users worldwide, are facing challenges in accessibility on the NHS due to strict eligibility criteria and high costs, despite their efficacy highlighted by clinical trials showing substantial weight loss in patients. #WeightLoss #ObesityCrisis #GLP1 #GB #US #DK
GLP-1 weight loss injections have emerged as a groundbreaking solution to the obesity crisis, with around 100 million users globally, as clinical trials and patient testimonials reveal significant weight loss results, although access issues and the high costs of these medications raise concerns about equitable treatment options in the UK. #WeightLoss #ObesityTreatment #HealthInnovation #GB #US #DK
The article discusses the rising dangers associated with the use of "skinny jabs" for weight loss in the UK, highlighting cases of adverse health effects, including a death connected to such treatments, and the challenges patients face in accessing these medications safely through the NHS due to strict eligibility criteria and high costs. #WeightLoss #HealthRisks #ObesityTreatment #GB
The article highlights the alarming trend of individuals in the UK suffering severe health issues or even death after using illegal weight loss injections, known as "skinny jabs," due to strict NHS access and affordability issues, prompting concerns from medical experts about the risks associated with counterfeit and shared medications. #WeightLoss #HealthRisks #ObesityTreatment #GB
Concerns are rising in the UK as the trend of using "skinny jabs" for weight loss has led to hospitalizations, including a recent death, due to unsafe practices and the inaccessibility of prescribed medications like Mounjaro and Wegovy, which are not available to many patients despite qualifying under NHS guidelines. #WeightLoss #HealthRisks #ObesityTreatment #GB
Concerns are rising in the UK as the trend of using "skinny jabs" for weight loss has led to hospitalizations, including a recent death, due to unsafe practices and the inaccessibility of prescribed medications like Mounjaro and Wegovy, which are not available to many patients despite qualifying under NHS guidelines. #WeightLoss #HealthRisks #ObesityTreatment #GB
A growing number of people in the UK are being hospitalized due to unsafe "skinny jabs," including a tragic case where a woman died after receiving a weight loss injection, prompting experts to warn against the dangers of illegally obtained drugs and the strict NHS criteria that limit access to legitimate treatments for obesity. #WeightLoss #HealthRisks #ObesityTreatment #GB
A new daily pill, orforglipron, may help individuals who stop using injectable weight-loss medications maintain their weight loss, as research indicates that patients using the pill were able to keep over 70% of the weight they lost, while those on a placebo maintained only 38-50%, with the study highlighting orforglipron's potential benefits in managing obesity as a chronic disease. #WeightLoss #ObesityTreatment #HealthInnovation #US #GB
A new daily pill called orforglipron may help individuals who stop using injectable weight loss medications maintain their weight loss, as a study shows that those taking the pill retained over 70% of their lost weight after a year, compared to 38-50% for the placebo group, with further research needed to determine the long-term effects of the treatment. #WeightLoss #ObesityTreatment #HealthResearch #US #GB
A new daily pill, orforglipron, has shown promise in helping individuals maintain weight loss after stopping injectable weight loss medications, with study participants who took the pill retaining over 70% of their weight loss, while those on a placebo maintained only 38-50%, suggesting a potential shift in obesity treatment methods. #WeightLoss #ObesityTreatment #HealthResearch #US #GB
